生物醫(yī)藥行業(yè)抗腫瘤靶向藥深度分析（二）療效為本，從臨床數(shù)據(jù)剖析六大類腫瘤靶向藥格局

1、正文目錄報告背景............................................................................................................................2報告特點...................................................................................

2、.........................................2一、中美癌癥患病情況對比：我國控癌之路任重道遠(yuǎn)...............................................61.1我國高發(fā)腫瘤缺乏有效靶向藥物.............................................61.2我國腫瘤患者死亡率遠(yuǎn)超發(fā)達(dá)國家..........................

3、.................7二、高發(fā)腫瘤靶向治療療效對比：少數(shù)腫瘤類型療效突出，多數(shù)無藥可用................82.1肺癌：新藥層出不窮，療效步步高升.........................................82.2結(jié)直腸癌：兩大靶向藥物占據(jù)主位，后來者乏力取代..........................152.3乳腺癌：生存期長，靶向藥物療效明顯..................

4、....................212.4胃癌：頑固腫瘤，靶向藥物缺乏............................................262.5肝癌：逐漸推出靶向藥物，免疫抑制劑初現(xiàn)優(yōu)異療效..........................292.6食管癌：尚無針對性靶向藥................................................31三、A股上市公司積極布局腫瘤靶向

5、藥物...............................................................313.1恒瑞醫(yī)藥................................................................313.2復(fù)星醫(yī)藥................................................................323.3貝達(dá)藥業(yè)

6、................................................................333.4麗珠集團(tuán)................................................................333.5科倫藥業(yè)................................................................34四、風(fēng)險提示..

7、.......................................................................................................34圖表33吡咯替尼二期臨床試驗結(jié)果...............................................24圖表34吡咯替尼與其他HER2抑制劑一線治療結(jié)果對比（單位：月）.................2

8、4圖表35治療乳腺癌的HER2小分子抑制劑對比.....................................24圖表36CDK46抑制劑聯(lián)合AI治療ERHER2晚期乳腺癌患者可獲得較好的效果（單位：月）25圖表37乳腺癌靶向藥物銷售情況.................................................26圖表38國內(nèi)治療CDK46抑制劑在研情況.........................

9、................26圖表39胃癌治療指南...........................................................26圖表40近年晚期胃癌靶向治療Ⅲ期臨床研究匯總...................................27圖表41胃癌一線精準(zhǔn)治療臨床試驗結(jié)果（單位：月）...............................28圖表42胃癌二線精準(zhǔn)治療臨床試

10、驗結(jié)果（單位：月）...............................28圖表43胃癌的三線治療.........................................................29圖表44肝癌治療方式...........................................................29圖表45晚期肝癌一線治療靶向藥物療效對比（單位：月）...........

11、................30圖表46晚期肝癌二線治療靶向藥物療效對比（單位：月）...........................30圖表47免疫抑制劑聯(lián)合抗血管生成藥治療晚期肝癌.................................31圖表48恒瑞醫(yī)藥在研腫瘤靶向藥物...............................................31圖表49復(fù)星醫(yī)藥在研腫瘤靶向藥物........

12、.......................................32圖表50貝達(dá)藥業(yè)在研腫瘤靶向藥物...............................................33圖表51麗珠集團(tuán)在研腫瘤靶向藥物...............................................33圖表52科倫藥業(yè)在研腫瘤靶向藥物.................................